Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.44 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.44 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.44 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.44 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.44 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4F8 | P98187 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7336391 | 0.82 | CSNK2A2 (0.45) | CYP2A6ARMAPT | |
| SCHEMBL13791027 | 0.78 | CYP1A1 (0.46) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL7326490 | 0.78 | MAOB (0.46) | CYP1A1CYP1A2CYP3A4CYP1B1AR | |
| SCHEMBL3904591 | 0.78 | CYP1A1 (0.44) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL27748366 | 0.75 | CYP1A1 (0.39) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL3102384 | 0.72 | AR (0.42) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL3104847 | 0.72 | CYP1A1 (0.42) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL3737979 | 0.71 | IKBKB (0.49) | CYP1A2CYP3A4CYP2C9CYP2C19MAPT | |
| SCHEMBL3105229 | 0.71 | CFTR (0.43) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL27930367 | 0.71 | RXRA (0.49) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210876-B1 | HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-8633184-B2 | Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-01-21 | — | — | US | disclosed |
| US-8633184-B2 | Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-01-21 | — | — | US | disclosed |
| CN-101479008-B | PPAR-delta agonist benzazepine-oxyacetic acid derivatives for raising HDL-C, lowering LDL-C and lowering cholesterol | JANSSEN PHARMACEUTICA NV | 2013-07-17 | — | — | CN | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| EP-2010289-B1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-30 | — | — | EP | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2210876-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-20100120748-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | CYMABAY THERAPEUTICS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100120748-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | CYMABAY THERAPEUTICS, INC. | 2010-05-13 | — | — | US | disclosed |
| CN-101479008-A | Benza -oxyacetic acid derivatives as PPAR-delta agonists for raising HDL-C, lowering LDL-C and lowering cholesterol | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-08 | — | — | CN | disclosed |
| EP-2010289-A2 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007121432-A2 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007121432-A2 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244094-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | CYMABAY THERAPEUTICS, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244094-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | CYMABAY THERAPEUTICS, INC. | 2007-10-18 | — | — | US | disclosed |
| US-5545645-A | Heterocyclic derivatives in the treatment of ischaemia and related diseases | SYNTEX PHARMACEUTICALS, LIMITED (GB) | 1996-08-13 | — | — | US | disclosed |
| EP-0693062-A1 | HETEROCYCLIC DERIVATIVES IN THE TREATMENT OF ISCHAEMIA AND RELATED DISEASES | SYNTEX PHARMACEUTICALS LTD. (GB) | 1996-01-24 | — | — | EP | disclosed |
| US-5428037-A | Piperazine derivatives; calcium and sodium channel antagonists | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1995-06-27 | — | — | US | disclosed |
| WO-1994024116-A1 | HETEROCYCLIC DERIVATIVES IN THE TREATMENT OF ISCHAEMIA AND RELATED DISEASES | SYNTEX PHARMACEUTICALS LIMITED (GB) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120748-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | PPARD, PPARG, PPARA | CYP1A1 732/4885CYP1A2 632/4885CYP2E1 379/4885 |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | GLP1R, GPR119, GCGR | CYP1A1 839/4885CYP1A2 1570/4885CYP2E1 1014/4885 |
| US-20070244094-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | PPARD, PPARG, PPARA | CYP1A1 732/4885CYP1A2 632/4885CYP2E1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.